CMO & CDMO - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509248252

Publication Date:

September 26, 2024

Pages:

111

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

At a time when pharmaceutical companies face increasing price pressures around the globe from key payers, including public and government insurance systems, reducing operational expenses is a major driver of outsourcing pharmaceutical manufacturing to CDMOs. Also, an increasing number of pharmaceutical companies are refocusing on their core capabilities and strengths, leading to divestments of in-house manufacturing capacities in some areas and to a gro
The global market for CMO & CDMO was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for CMO & CDMO was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for CMO & CDMO was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for CMO & CDMO was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of CMO & CDMO include Recipharm, AMRI3, Patheon, Aenova, Catalent, Amatsigroup, WuXi PharmaTech, Strides Shasun and Piramal, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for CMO & CDMO, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of CMO & CDMO by region & country, by Type, and by Application.
The CMO & CDMO market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CMO & CDMO.
麻豆原创 Segmentation
By Company
Recipharm
AMRI3
Patheon
Aenova
Catalent
Amatsigroup
WuXi PharmaTech
Strides Shasun
Piramal
Siegfried
Segment by Type:
Development
API production
Formulation
Segment by Application
Pharmaceutical Industry
Biotechnology
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of CMO & CDMO manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of CMO & CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of CMO & CDMO in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 CMO & CDMO Product Introduction
1.2 Global CMO & CDMO 麻豆原创 Size Forecast
1.3 CMO & CDMO 麻豆原创 Trends & Drivers
1.3.1 CMO & CDMO Industry Trends
1.3.2 CMO & CDMO 麻豆原创 Drivers & Opportunity
1.3.3 CMO & CDMO 麻豆原创 Challenges
1.3.4 CMO & CDMO 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global CMO & CDMO Players Revenue Ranking (2023)
2.2 Global CMO & CDMO Revenue by Company (2019-2024)
2.3 Key Companies CMO & CDMO Manufacturing Base Distribution and Headquarters
2.4 Key Companies CMO & CDMO Product Offered
2.5 Key Companies Time to Begin Mass Production of CMO & CDMO
2.6 CMO & CDMO 麻豆原创 Competitive Analysis
2.6.1 CMO & CDMO 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by CMO & CDMO Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CMO & CDMO as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Development
3.1.2 API production
3.1.3 Formulation
3.2 Global CMO & CDMO Sales Value by Type
3.2.1 Global CMO & CDMO Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global CMO & CDMO Sales Value, by Type (2019-2030)
3.2.3 Global CMO & CDMO Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Pharmaceutical Industry
4.1.2 Biotechnology
4.1.3 Other
4.2 Global CMO & CDMO Sales Value by Application
4.2.1 Global CMO & CDMO Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global CMO & CDMO Sales Value, by Application (2019-2030)
4.2.3 Global CMO & CDMO Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global CMO & CDMO Sales Value by Region
5.1.1 Global CMO & CDMO Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global CMO & CDMO Sales Value by Region (2019-2024)
5.1.3 Global CMO & CDMO Sales Value by Region (2025-2030)
5.1.4 Global CMO & CDMO Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America CMO & CDMO Sales Value, 2019-2030
5.2.2 North America CMO & CDMO Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe CMO & CDMO Sales Value, 2019-2030
5.3.2 Europe CMO & CDMO Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific CMO & CDMO Sales Value, 2019-2030
5.4.2 Asia Pacific CMO & CDMO Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America CMO & CDMO Sales Value, 2019-2030
5.5.2 South America CMO & CDMO Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa CMO & CDMO Sales Value, 2019-2030
5.6.2 Middle East & Africa CMO & CDMO Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions CMO & CDMO Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions CMO & CDMO Sales Value
6.3 United States
6.3.1 United States CMO & CDMO Sales Value, 2019-2030
6.3.2 United States CMO & CDMO Sales Value by Type (%), 2023 VS 2030
6.3.3 United States CMO & CDMO Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe CMO & CDMO Sales Value, 2019-2030
6.4.2 Europe CMO & CDMO Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe CMO & CDMO Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China CMO & CDMO Sales Value, 2019-2030
6.5.2 China CMO & CDMO Sales Value by Type (%), 2023 VS 2030
6.5.3 China CMO & CDMO Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan CMO & CDMO Sales Value, 2019-2030
6.6.2 Japan CMO & CDMO Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan CMO & CDMO Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea CMO & CDMO Sales Value, 2019-2030
6.7.2 South Korea CMO & CDMO Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea CMO & CDMO Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia CMO & CDMO Sales Value, 2019-2030
6.8.2 Southeast Asia CMO & CDMO Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia CMO & CDMO Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India CMO & CDMO Sales Value, 2019-2030
6.9.2 India CMO & CDMO Sales Value by Type (%), 2023 VS 2030
6.9.3 India CMO & CDMO Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Recipharm
7.1.1 Recipharm Profile
7.1.2 Recipharm Main Business
7.1.3 Recipharm CMO & CDMO Products, Services and Solutions
7.1.4 Recipharm CMO & CDMO Revenue (US$ Million) & (2019-2024)
7.1.5 Recipharm Recent Developments
7.2 AMRI3
7.2.1 AMRI3 Profile
7.2.2 AMRI3 Main Business
7.2.3 AMRI3 CMO & CDMO Products, Services and Solutions
7.2.4 AMRI3 CMO & CDMO Revenue (US$ Million) & (2019-2024)
7.2.5 AMRI3 Recent Developments
7.3 Patheon
7.3.1 Patheon Profile
7.3.2 Patheon Main Business
7.3.3 Patheon CMO & CDMO Products, Services and Solutions
7.3.4 Patheon CMO & CDMO Revenue (US$ Million) & (2019-2024)
7.3.5 Aenova Recent Developments
7.4 Aenova
7.4.1 Aenova Profile
7.4.2 Aenova Main Business
7.4.3 Aenova CMO & CDMO Products, Services and Solutions
7.4.4 Aenova CMO & CDMO Revenue (US$ Million) & (2019-2024)
7.4.5 Aenova Recent Developments
7.5 Catalent
7.5.1 Catalent Profile
7.5.2 Catalent Main Business
7.5.3 Catalent CMO & CDMO Products, Services and Solutions
7.5.4 Catalent CMO & CDMO Revenue (US$ Million) & (2019-2024)
7.5.5 Catalent Recent Developments
7.6 Amatsigroup
7.6.1 Amatsigroup Profile
7.6.2 Amatsigroup Main Business
7.6.3 Amatsigroup CMO & CDMO Products, Services and Solutions
7.6.4 Amatsigroup CMO & CDMO Revenue (US$ Million) & (2019-2024)
7.6.5 Amatsigroup Recent Developments
7.7 WuXi PharmaTech
7.7.1 WuXi PharmaTech Profile
7.7.2 WuXi PharmaTech Main Business
7.7.3 WuXi PharmaTech CMO & CDMO Products, Services and Solutions
7.7.4 WuXi PharmaTech CMO & CDMO Revenue (US$ Million) & (2019-2024)
7.7.5 WuXi PharmaTech Recent Developments
7.8 Strides Shasun
7.8.1 Strides Shasun Profile
7.8.2 Strides Shasun Main Business
7.8.3 Strides Shasun CMO & CDMO Products, Services and Solutions
7.8.4 Strides Shasun CMO & CDMO Revenue (US$ Million) & (2019-2024)
7.8.5 Strides Shasun Recent Developments
7.9 Piramal
7.9.1 Piramal Profile
7.9.2 Piramal Main Business
7.9.3 Piramal CMO & CDMO Products, Services and Solutions
7.9.4 Piramal CMO & CDMO Revenue (US$ Million) & (2019-2024)
7.9.5 Piramal Recent Developments
7.10 Siegfried
7.10.1 Siegfried Profile
7.10.2 Siegfried Main Business
7.10.3 Siegfried CMO & CDMO Products, Services and Solutions
7.10.4 Siegfried CMO & CDMO Revenue (US$ Million) & (2019-2024)
7.10.5 Siegfried Recent Developments
8 Industry Chain Analysis
8.1 CMO & CDMO Industrial Chain
8.2 CMO & CDMO Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 CMO & CDMO Sales Model
8.5.2 Sales Channel
8.5.3 CMO & CDMO Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Recipharm
AMRI3
Patheon
Aenova
Catalent
Amatsigroup
WuXi PharmaTech
Strides Shasun
Piramal
Siegfried

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.